Khan A, Sergi C. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics. 2018;8:29.

Article  PubMed  PubMed Central  Google Scholar 

Bonten E, van der Spoel A, Fornerod M, Grosveld G, d’Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996;10:3156–69.

Article  CAS  PubMed  Google Scholar 

Caciotti A, Melani F, Tonin R, Cellai L, Catarzi S, Procopio E, et al. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: an overview. Mol Genet Metab. 2020;129:47–58.

Arora V, Setia N, Dalal A, Vanaja MC, Gupta D, Razdan T, et al. Sialidosis type II: expansion of phenotypic spectrum and identification of a common mutation in seven patients. Mol Genet Metab Rep. 2020;22:100561.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonten EJ, Annunziata I, d’Azzo A. Lysosomal multienzyme complex: pros and cons of working together. Cell Mol Life Sci. 2014;71:2017–32.

Article  CAS  PubMed  Google Scholar 

Bonten EJ, Campos Y, Zaitsev V, Nourse A, Waddell B, Lewis W, et al. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization. J Biol Chem. 2009;284:28430–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mosca R, van de Vlekkert D, Campos Y, Fremuth LE, Cadaoas J, Koppaka V, et al. Conventional and unconventional therapeutic strategies for sialidosis type I. J Clin Med. 2020;9:695.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Bonten EJ, Yogalingam G, Mann L, d’Azzo A. Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol Genet Metab. 2005;85:181–9.

Article  CAS  PubMed  Google Scholar 

Bonten EJ, Wang D, Toy JN, Mann L, Mignardot A, Yogalingam G, et al. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J. 2004;18:971–3.

Article  CAS  PubMed  Google Scholar 

Cadaoas J, Hu H, Boyle G, Gomero E, Mosca R, Jayashankar K, et al. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept. Mol Ther Methods Clin Dev. 2021;20:191–203.

Article  CAS  PubMed  Google Scholar 

Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1:427–51.

Article  PubMed  Google Scholar 

Hu H, Mosca R, Gomero E, van de Vlekkert D, Campos Y, Fremuth LE, et al. AAV-mediated gene therapy for galactosialidosis: a long-term safety and efficacy study. Mol Ther Methods Clin Dev. 2021;23:644–58.

Article  PubMed  PubMed Central  Google Scholar 

Bonten EJ, Yogalingam G, Hu H, Gomero E, van de Vlekkert D, d’Azzo A. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta. 2013;1832:1784–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta AO, Patterson MC, Wood T, Eisengart JB, Orchard PJ, Lund TC. Hematopoietic cell transplantation for sialidosis type I. Mol Genet Metab Rep. 2022;30:100832.

Article  CAS  PubMed  Google Scholar 

d’Azzo A, Machado E, Annunziata I. Pathogenesis, emerging therapeutic targets and treatment in sialidosis. Expert Opin Orphan Drugs. 2015;3:491–504.

Article  PubMed  PubMed Central  Google Scholar 

Lai SC, Chen RS, Wu Chou YH, Chang HC, Kao LY, Huang YZ, et al. A longitudinal study of Taiwanese sialidosis type 1: an insight into the concept of cherry-red spot myoclonus syndrome. Eur J Neurol. 2009;16:912–9.

Article  PubMed  Google Scholar 

Huang YZ, Lai SC, Lu CS, Weng YH, Chuang WL, Chen RS. Abnormal cortical excitability with preserved brainstem and spinal reflexes in sialidosis type I. Clin Neurophysiol. 2008;119:1042–50.

Article  PubMed  Google Scholar 

Fan SP, Lee NC, Lin CH. Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene. J Formos Med Assoc. 2020;119:406–12.

Article  CAS  PubMed  Google Scholar 

Lin CC, Shen YR, Chang CC, Guo XY, Young YY, Lai TY, et al. Terminal uridyltransferase 7 regulates TLR4-triggered inflammation by controlling Regnase-1 mRNA uridylation and degradation. Nat Commun. 2021;12:3878.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Lee NC, Shieh YD, Chien YH, Tzen KY, Yu IS, Chen PW, et al. Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency. Neurobiol Dis. 2013;52:177–90.

Article  CAS  PubMed  Google Scholar 

Sleigh JN, West SJ, Schiavo G. A video protocol for rapid dissection of mouse dorsal root ganglia from defined spinal levels. BMC Res Notes. 2020;13:302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Geest N, Bonten E, Mann L, de Sousa-Hitzler J, Hahn C, d’Azzo A. Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice. Hum Mol Genet. 2002;11:1455–64.

Article  PubMed  Google Scholar 

Liang F, Seyrantepe V, Landry K, Ahmad R, Ahmad A, Stamatos NM, et al. Monocyte differentiation up-regulates the expression of the lysosomal sialidase, Neu1, and triggers its targeting to the plasma membrane via major histocompatibility complex class II-positive compartments. J Biol Chem. 2006;281:27526–38.

Article  CAS  PubMed  Google Scholar 

Agarwal S. High-dose AAV gene therapy deaths. Nat Biotechnol. 2020;38:910.

Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39:47–55.

Article  CAS  PubMed  Google Scholar 

Weiss C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6:17–27.

Article  CAS  PubMed  Google Scholar 

Hinderer C, Bell P, Katz N, Vite CH, Louboutin JP, Bote E, et al. Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther. 2018;29:15–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB, et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol Ther. 2020;28:411–21.

Article  CAS  PubMed  Google Scholar 

Uchihara T, Ohashi K, Kitagawa M, Kurata M, Nakamura A, Hirokawa K, et al. Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia. Acta Neuropathol. 2010;119:135–45.

Article  CAS  PubMed  Google Scholar 

Hordeaux J, Buza EL, Dyer C, Goode T, Mitchell TW, Richman L, et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gene Ther. 2020;31:808–18.

Article  CAS  PubMed  Google Scholar 

Lundstrom K. Viral vectors in gene therapy. Diseases. 2018;6:42.

Article  PubMed  PubMed Central  Google Scholar 

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359:eaan4672.

Article  PubMed  Google Scholar 

Das S, Huang S, Lo AW. Acceleration of rare disease therapeutic development: a case study of AGIL-AADC. Drug Discov Today. 2019;24:678–84.

Article  CAS  PubMed  Google Scholar 

Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022;30:509–18.

Article  CAS  PubMed  Google Scholar 

Howlader MA, Demina EP, Samarani S, Guo T, Caillon A, Ahmad A, et al. The Janus-like role of neuraminidase isoenzymes in inflammation. FASEB J. 2022;36:e22285.

Article  CAS  PubMed  Google Scholar 

Rama Rao KV, Kielian T. Astrocytes and lysosomal storage diseases. Neuroscience. 2016;323:195–206.

Article  CAS  PubMed  Google Scholar 

van de Vlekkert D, Demmers J, Nguyen XX, Campos Y, Machado E, Annunziata I, et al. Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis. Sci Adv. 2019;5:eaav3270.

Article  ADS  PubMed  PubMed C